We Told You at $1.59 — Now It’s Up 35%. But Are We Still Early?

This handheld ultrasound disruptor just proved our thesis right. The next move could be even bigger.

Imagine being on the edge of a quiet revolution in healthcare technology—where a device once reserved for hospital radiology suites is finding its way into ambulances, clinics, even remote villages. Two months ago, we flagged a company trading at $1.59 that most investors still regarded as a micro-cap curiosity. Today that same firm trades around $2.51—up roughly ~35%—and the market is beginning to stir. The reason? A combination of improved execution, tighter cost discipline, and a vision of imaging that fits in your pocket. We told you about this story on August 27, 2025, at that modest price, and now you’re already ahead. But here’s the key question: Is this simply the payoff for a short-term thesis, or the first leg of a much deeper structural shift? Because if you’re right early enough in a narrative like this, the asymmetric upside can far outweigh the risk. We believe we are there. Let’s pull back the curtain and explore what lies behind the move—and why playing it now matters.